Aspirin May Slow Decline in Mental Capacity Among Elderly Patients, Swedish Study Suggests

Source: ScienceDaily (10/22/12)

"In addition to preventing heart disease, acetylsalicylic acid has been shown to be effective against cancer according to several scientific studies. It is common practice in many countries to treat women at risk for heart disease with a small dose of acetylsalicylic acid."

A daily dose of acetylsalicylic acid equivalent to a fourth of an aspirin may slow the decline in intellectual capacity among elderly individuals with high cardiovascular risk. This is shown in a study by Sahlgrenska Academy, University of Gothenburg, Sweden.

Researchers at Sahlgrenska Academy, University of Gothenburg, over a five-year period studied how intellectual capacity changes among 681 elderly women (70 to 92 years) with heightened risk of suffering from a heart attack, vascular spasm or stroke.

Of the 681 women, 129 received a low daily dose of acetylsalicylic acid, equivalent to a fourth of an aspirin, to prevent heart disease. The Gothenburg study shows that acetylsalicylic acid also slowed decline in brain capacity among the elderly women. . .View Full Article

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain
Source: Streetwise Reports (11/26/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers.

US$12 Billion RNA Deal Triggers Sector Shakeup
Source: Streetwise Reports (11/14/2025)

Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Source: Streetwise Reports (11/13/2025)

aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.

Preclinical Compounds Perform Better Than Existing Drugs
Source: Dr. Douglas Loe (11/13/2025)

Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Source: Streetwise Reports (11/12/2025)

Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.